Cargando…
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer
PURPOSE: Triple-negative breast cancer (TNBC) is characterized by large heterogeneity and relative lack of available targeted therapies. To find therapeutic strategies for distinct patients with TNBC, several approaches have been used for TNBC clustering, including recently immune and phosphoproteom...
Autores principales: | Jimeno, Rebeca, Mouron, Silvana, Salgado, Roberto, Loi, Sherene, Pérez-Mies, Belén, Sánchez-Bayona, Rodrigo, Manso, Luis, Martínez, Mario, Garrido-García, Ana, Serrano-Pardo, Rosario, Colomer, Ramón, Quintela-Fandino, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025236/ https://www.ncbi.nlm.nih.gov/pubmed/36508123 http://dx.doi.org/10.1007/s12094-022-03006-3 |
Ejemplares similares
-
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach
por: Bueno, Maria J, et al.
Publicado: (2017) -
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021) -
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement
por: Colomer, Ramon, et al.
Publicado: (2023) -
Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer
por: Mouron, Silvana, et al.
Publicado: (2021) -
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019)